文献速递胸部肿瘤

肺癌移码突变的临床与免疫学意义

Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2019-06-22

本研究利用癌症基因组图谱数据分析移码突变与肿瘤突变负荷、新抗原负荷及免疫微环境的关系,并利用122例接受免疫检查点抑制剂治疗的NSCLC患者临床数据评估移码突变对疾病缓解率和生存结局的影响。结果显示移码突变与肿瘤突变负荷及活化CD4/CD8 T细胞浸润正相关,与无进展生存期延长、总缓解率和疾病控制率提高相关。作者认为移码突变可能对NSCLC的免疫检查点抑制剂反应具有预测作用。

要点

  • 移码突变负荷与肿瘤突变负荷及活化CD4/CD8 T细胞浸润呈正相关。
  • 有移码突变者接受免疫检查点抑制剂后中位无进展生存期6.2个月 vs 2.7个月(p=0.01)。
  • 有移码突变者总缓解率26% vs 12%(p=0.04),疾病控制率68% vs 48%(p=0.02)。

核心结论

  • 作者认为移码突变可能对NSCLC的免疫检查点抑制剂反应具有预测作用。

研究设计与样本

  • 利用癌症基因组图谱数据集分析移码突变状态与肿瘤突变负荷、新抗原负荷及免疫微环境的关系。
  • 利用122例接受免疫检查点抑制剂治疗的NSCLC患者临床数据评估移码突变对疾病缓解率和生存结局的影响。

主要发现

  • 移码突变负荷与肿瘤突变负荷及活化CD4/CD8 T细胞浸润呈正相关。
  • 有移码突变者接受免疫检查点抑制剂后中位无进展生存期6.2个月 vs 无移码突变者2.7个月(p=0.01)。
  • 有移码突变者总缓解率26% vs 无移码突变者12%(p=0.04)。
  • 有移码突变者疾病控制率68% vs 无移码突变者48%(p=0.02)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Presently, programmed death ligand 1 is the most commonly used biomarker to predict response to immune checkpoint inhibitors (ICIs) in NSCLC. Owing to its several limitations, there is continuous search for more precise and reliable markers. Frameshift mutations by insertion or deletion (fsindels) are suggested to induce more immunogenic tumor-specific neoantigens, conferring better response to ICIs. Positive correlation of fsindels with ICI response has been studied in melanoma and renal cell carcinoma. We investigated the implication of fsindels in the clinical outcomes and immune landscape of patients with NSCLC treated with ICIs. METHODS: We utilized The Cancer Genome Atlas data set to analyze tumor mutational burden, neoantigen burden, and immune landscape in relation to fsindel status. In addition, utilizing the clinical data from 122 patients treated with ICIs, we evaluated the influence of fsindels on disease response rates and survival outcomes. RESULTS: A positive correlation between fsindel burden and tumor mutational burden and activated CD4/CD8 T-cell infiltration was shown. Presence of fsindels was also associated with significant prolongation of progression-free survival in patients treated with ICIs (median 6.2 versus 2.7 months [p = 0.01]). In addition, significant differences in the overall response rates (26% versus 12% [p = 0.04]) and disease control rates (68% versus 48% [p = 0.02]) were observed in patients with fsindels. CONCLUSION: Our findings suggest that fsindels may have a predictive role for ICI response in NSCLC.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Chae YK, Viveiros P, Lopes G, et al. Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer. J Thorac Oncol. 2019. PMID: 31238177. doi:10.1016/j.jtho.2019.06.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。